ArticleNature medicine2018
Author Correction: High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy.
Article in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer.The Journal of clinical investigation · 2022Trial
- Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in Pancreatic Cancer.Biomolecules · 2025Article
- Unveiling the influence of tumor and immune signatures on immune checkpoint therapy in advanced lung cancer.eLife · 2024Article
- Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood.Cancer research communications · 2024Article
- Interleukin-1 regulates follicular T cells during the germinal center reaction.Frontiers in immunology · 2024Article
- Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer.Journal for immunotherapy of cancer · 2023Review
- Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade.Journal for immunotherapy of cancer · 2022Article
- Host response to immune checkpoint inhibitors contributes to tumor aggressiveness.Journal for immunotherapy of cancer · 2021Article
- Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs.Cancers · 2021Article
- Biomimetic Anti-PD-1 Peptide-Loaded 2D FePSeAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- muscat detects subpopulation-specific state transitions from multi-sample multi-condition single-cell transcriptomics data.Nature communications · 2020Article
- Review
- Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade.Frontiers in immunology · 2020Review
Corrections and comments
- Erratum for
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the version of this article initially published, Figs. 5a,c and 6a were incorrect because of an error in a metadata spreadsheet that led to the healthy donor patient 2 (HD2) samples being used twice in the analysis of baseline samples and in the analysis at 12 weeks of anti-PD-1 therapy, while HD3 samples had not been used.
Identifiers
29967347What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.